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UBA1/GARS-dependent pathways drive
sensory-motor connectivity defects in spinal
muscular atrophy
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Deafferentation of motor neurons as a result of defective sensory-motor connectivity is a critical early event in the pathogenesis of
spinal muscular atrophy, but the underlying molecular pathways remain unknown. We show that restoration of ubiquitin-like
modiﬁer-activating enzyme 1 (UBA1) was sufﬁcient to correct sensory-motor connectivity in the spinal cord of mice with spinal
muscular atrophy. Aminoacyl-tRNA synthetases, including GARS, were identiﬁed as downstream targets of UBA1. Regulation of
GARS by UBA1 occurred via a non-canonical pathway independent of ubiquitylation. Dysregulation of UBA1/GARS pathways in
spinal muscular atrophy mice disrupted sensory neuron fate, phenocopying GARS-dependent defects associated with Charcot-
Marie-Tooth disease. Sensory neuron fate was corrected following restoration of UBA1 expression and UBA1/GARS pathways in
spinal muscular atrophy mice. We conclude that defective sensory motor connectivity in spinal muscular atrophy results from
perturbations in a UBA1/GARS pathway that modulates sensory neuron fate, thereby highlighting signiﬁcant molecular and
phenotypic overlap between spinal muscular atrophy and Charcot-Marie-Tooth disease.
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Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive
form of motor neuron disease with an incidence of 1 in
10 000 live births (Sugarman et al., 2012; Verhaart et al.,
2017; Groen et al., 2018b). SMA is characterized primarily
by degeneration of lower motor neurons in the anterior horn
of the spinal cord. This is accompanied by proximal muscle
weakness and atrophy, resulting in a progressive decline in
motor function and, in severe cases, paralysis and death (Kolb
and Kissel, 2011; Shorrock et al., 2018). Recently, compelling
evidence has been put forward from several studies demon-
strating that sensory neuron defects are a signiﬁcant feature of
SMA pathogenesis. For example, a reduction in numbers of
myelinated dorsal root axons has been reported (Ling et al.,
2010), alongside signiﬁcant reductions in the number of pro-
prioceptive synapses formed onto motor neurons in the spinal
cord (Ling et al., 2010; Mentis et al., 2011; Fletcher et al.,
2017). The deafferentation of motor neurons as a result of
defective sensory-motor connectivity is now known to be a
critical early event in the pathogenesis of SMA, where it rep-
resents a primary cause of motor neuron dysfunction (Ling
et al., 2010; Mentis et al., 2011; Simon et al., 2017).
Similarly, it has previously been shown that sensory nerve
endings innervating embryonic footpads display defective out-
growth and altered neuron terminal structure in SMA mice
(Jablonka et al., 2006). Although defects in sensory neuron
outgrowth and altered b-actin protein and mRNA localiza-
tion have been reported in cultured sensory neurons from
SMA mice (Jablonka et al., 2006), the molecular mechanisms
underlying defective sensory-motor connectivity in SMA are
still to be established.
In 95% of cases, SMA is caused by homozygous deletion
of the survival motor neuron 1 gene (SMN1), which encodes
the survival motor neuron protein (SMN) (Lefebvre et al.,
1995). Interestingly, however, not all forms of SMA are
caused by deletions or mutations in the SMN1 gene.
Mutations in the ubiquitin-like modiﬁer activating enzyme 1
gene (UBA1) cause a rare form of SMA known as X-linked
SMA (XL-SMA) (Ramser et al., 2008; Dlamini et al., 2013;
Jedrzejowska et al., 2015). UBA1 encodes the primary
enzyme, UBA1, responsible for activating ubiquitin as the
ﬁrst step in the ubiquitin-conjugation pathway, to mark pro-
teins for degradation by the proteasome (Groen and
Gillingwater, 2015). XL-SMA is clinically similar to SMA
and is characterized by loss of lower motor neurons, muscle
weakness, hypotonia and a lack of reﬂexes. In addition, con-
genital contractures and fractures are also commonly asso-
ciated with XL-SMA (Ramser et al., 2008; Dlamini et al.,
2013; Jedrzejowska et al., 2015). Mutations in UBA1 under-
lying XL-SMA are predicted to cause instability of the
enzyme, leading to a reduction in expression levels of UBA1
(Ramser et al., 2008; Lao et al., 2012; Balak et al., 2017).
Recent ﬁndings have suggested that altered ubiquitin
homeostasis is a core molecular feature of SMN1-dependent
SMA, with reduced UBA1 expression central to this disruption
in a range of animal models and in SMA patient-derived iPSC
motor neurons (Aghamaleky Sarvestany et al., 2014; Wishart
et al., 2014; Fuller et al., 2015; Powis et al., 2016).
Suppression or pharmacological inhibition of UBA1 is sufﬁ-
cient to induce an SMA-like neuromuscular phenotype in zeb-
raﬁsh (Wishart et al., 2014) and, similarly, pharmacological
inhibition of UBA1 in Schwann cells recapitulates the defective
myelination phenotype observed in SMA (Aghamaleky
Sarvestany et al., 2014; Hunter et al., 2014). Consistent
with this, therapies that restore UBA1 have shown beneﬁcial
effects on neuromuscular phenotypes in several SMA models
(Powis et al., 2016). SMA mice treated with adeno-associated
virus serotype 9 (AAV9) expressing full-length human UBA1
cDNA (AAV9-UBA1) show increased survival compared to
untreated SMA mice, along with improvements in systemic
(e.g. heart and liver) pathology. SMA mice treated with
AAV9-UBA1 also showed a rescue of the number of motor
neuron cell bodies in the spinal cord, an increase in muscle
ﬁbre diameter, and rescue of NMJ innervation defects com-
pared to untreated SMA mice (Powis et al., 2016).
Because of the wide ranging therapeutic beneﬁts of treat-
ment with AAV9-UBA1 and the relevance of UBA1-
mediated degeneration for multiple types of SMA, here,
we set out to determine whether UBA1-dependent
pathways are responsible for mediating defective sensory-
motor connectivity in SMA and to identify UBA1 depend-
ent mediators of degeneration. We report that elevation of
UBA1 levels via AAV9 gene therapy in vivo was sufﬁcient
to correct sensory-motor connectivity defects in SMA mice,
acting via UBA1’s regulation of aminoacyl-tRNA synthe-
tases, including GARS, in sensory neurons.
Materials and methods
Study approvals
All animal studies were approved by the internal ethics com-
mittee at the University of Edinburgh and were performed
under the authority of relevant project and personal licenses
from the UK Home Ofﬁce.
Animal models and UBA1
overexpression in vivo
Taiwanese SMA mice (Smn/; SMN2tg/0) (Hsieh-Li et al.,
2000; Riessland et al., 2010), on a congenic FVB background,
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were originally obtained from Jackson Laboratories (strain no.
005058) and maintained according to established breeding
protocols (Riessland et al., 2010). Phenotypically-normal het-
erozygous (Smn+ /; SMN2tg/0) littermates were used as con-
trols. Wild-type FVB mice were obtained from in-house
breeding stocks at the University of Edinburgh. Mice were
maintained under standard speciﬁc pathogen-free conditions
and retrospectively genotyped using standard PCR protocols.
To overexpress UBA1 in vivo, mice were injected with
AAV9-UBA1 intravenously on the day of birth (Powis et al.,
2016). AAV9-UBA1 (Vigene) was administered at a concentra-
tion of 7  1013 viral genomes. Mice underwent general
chilled anaesthesia and were then injected with 10 ml of
AAV9-UBA1 into the facial vein using a Hamilton syringe
ﬁtted with a Hamilton 33-gauge RN needle. Litters of mice
were randomly assigned to treatment groups. For all subse-
quent analyses, the observer was blinded to the disease/treat-
ment status of the mice.
Tissue isolation and preparation
Mice were sacriﬁced by overdose of anaesthetic at postnatal
Day 8, a late-symptomatic stage of disease progression. Spinal
cord dissection was performed as previously described (Powis
and Gillingwater, 2016). For quantitative ﬂuorescent western
blot analysis, isolated spinal cords were snap-frozen on dry ice
and stored at 80C. For immunohistochemistry, spinal cords
were ﬁxed in 4% paraformaldehyde (PFA) (Electron
Microscopy Sciences) for 24 h and cryopreserved in 30% su-
crose for 24 h at 4C. Lumbar regions of spinal cord were
embedded in O.C.T. (Cell Path), sectioned at 25 mm on a cryo-
stat, immediately collected onto SuperFrost PlusTM microscope
slides (Thermo Scientiﬁc) and stored at 20C.
For immunohistochemistry of lumbar dorsal root ganglia
(DRG), spinal columns were dissected from postnatal Day 8
mice, cut transversely at the T13 vertebrae, ﬁxed for 6 h in 4%
PFA, and cryopreserved in 30% sucrose for 24 h at 4C.
Lumbar and lower thoracic regions were embedded in
O.C.T. and cryosectioned at 12 mm. Using the T13 DRGs,
spinal columns were aligned so that the DRGs on each side
of the column were symmetrical, sections from L1 and L2
DRGs were collected onto SuperFrost PlusTM microscope
slides. For quantitative ﬂuorescent western blot analysis
lumbar dorsal root ganglia were dissected out of the spinal
column using a previously described method (Sleigh et al.,
2016). For each mouse, three DRGs from each half of the
lumbar spinal column were dissected so that western blots
were performed on six DRGs per mouse.
Cell culture and transfection
HEK293 cells (European Collection of Authenticated Cell
Cultures) were grown in high glucose Dulbecco’s modiﬁed
Eagle medium (Life Technologies) supplemented with 10% heat
inactivated foetal bovine serum (FBS; Sigma), penicillin/streptavi-
din (Invitrogen) and L-glutamine (Invitrogen). HEK293 cells were
transfected with RNAiMAX (Invitrogen) and 2.5mM Silencer
Select Validated UBA1 siRNA (s601, targeted against exons 24
and 25; Life Technologies), or with LipofectamineTM (Invitrogen)
and 3.5mg pCMV6-XL4-UBA1 plasmid (Origene) for proteomics
samples. For proteomics, three separate transfections were
combined per sample with three samples per condition.
For co-transfection of multiple plasmids, 1.25mg of each plasmid
was used and the same amount of DNA and LipofectamineTM/
RNAiMax was added to each well: pCMV6-XL4-UBA1
(Origene), pCMV6-Entry (Origene); pEGFP-GARS-N2 (gift
from Dr Antonelli Antonellis), pEGFP-N1 (gift from Prof.
Mike Cousin); pcDNA3.1-HA-Ubiquitin (gift from Prof. Yeh),
Addgene plasmid #18712 (Kamitani et al., 1997), pcDNA3.1+
(gift from Prof. Mike Cousin); pcDNA3.1-SMN-V5-His.
Negative control 2 siRNA (Life Technologies) was used as a
control for UBA1 siRNA. For all co-transfections, cells were har-
vested 48h after transfection.
Ubiquitylation assay
Following transfection, 10 mM of MG132 proteasome inhibitor
was added to HEK293 cells for 90min. Cells were lysed in
RIPA buffer (Fisher Scientiﬁc) containing 1% protease inhibi-
tor cocktail (Life Technologies), 1% phosphatase inhibitor
(Life Technologies) and 10mM N-ethylmaleimide (Sigma).
The lysate was incubated with 0.5mg anti-GFP primary anti-
body for 1 h 20min at 4C before incubation with protein A
magnetic beads (Life Technologies) for 40 mins at 4C.
Immunoprecipitates were then washed four times in NP40
buffer. Immunoprecipitates and input controls were probed
with the indicated antibodies.
Protein extraction and western
blotting
Protein was extracted in RIPA buffer with 1% protease inhibitor
cocktail, homogenized using a motorized disposable pestle
mixer. Protein concentration was determined using a BCA
assay (ThermoScientiﬁc). Proteins were separated on a 4–12%
gradient gel (Novex) and blotted using PVDF membrane stacks
using the iBlot system (Life Technologies). Western blotting
was performed using primary antibodies against SMN
(1:1000, BD Transduction Laboratories), UBA1 (1:1000,
Thermo, PA5–17274), GARS (1:2500, Abcam, ab42905),
YARS (1:1000, Abcam, ab154819), HA (1:1000, CST,
3724P), GFP (1:5000, Abcam, ab290) and the appropriate
IRDye secondary antibodies (LICOR). Tissue and cell-type ap-
propriate loading controls were: histone H3 (1:5000, Abcam,
ab1791), CoxIV (1:1000, Abcam, ab14744), a-Tubulin
(1:5000, Abcam, ab7291), GAPDH (1: 2500, Abcam, ab9484)
and Ponceau S total protein stain. Membranes were scanned on
an Odyssey imager (LICOR; Eaton et al., 2013) and analysed
using ImageStudio (LICOR).
Immunohistochemistry
Spinal cord and spinal column sections were permeabilized in
0.3% TritonTM X-100 (Sigma) in PBS for 10min at room
temperature, blocked in 4% BSA, 0.1% TritonTM X-100 in
PBS for 1 h and incubated in primary antibodies in a 1:4 di-
lution of blocking solution at 4C for 24 h. Slides were washed
in PBS and incubated with appropriate Alexa Fluor-labelled
secondary antibodies (1:400; Life Technologies) for 1 h at
room temperature and subsequently in DAPI (Life
Technologies) for 10min. For immunohistochemistry of
NF200, peripherin, parvalbumin and cleaved caspase 3,
spinal column sections were thawed at room temperature for
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1 h and permeabilized in 0.3% TritonTM X-100 in PBS (PBST)
for 3  10 mins at room temperature, and blocked in 10%
BSA in PBST for 1 h. Sections were then incubated with pri-
mary antibodies in blocking solution, at 4C for 24 h. Slides
were washed and sections incubated with the appropriate
Alexa Fluor-labelled secondary antibodies (1:400; Life
Technologies) in PBS for 1 h at room temperature and incu-
bated in DAPI for 10min. All slides were mounted and cover-
slipped in a 10% Mowiol solution (Polyscience). The
following primary antibodies were used in this study: GARS,
Abcam, ab42905, 1:500; UBA1a, CST, 4890S, 1:200; ChAT,
Millipore, AB144P, 1:100; VGlut1, synaptic systems, 135 302,
1:1000; SMI32, Covance, SMI-32R, 1:1000; NF200, Sigma,
N0142, 1:500; peripherin, Merck, AB1530, 1:500; parvalbu-
min, Swant, PV27, 1:1000; bIII-tubulin, Abcam, ab41489,
1:500; cleaved caspase-3, CST, 9661, 1:500.
Imaging and analysis
Imaging was performed on a Nikon A1R FILM at the
IMPACT facility, University of Edinburgh, or a Zeiss
LSM710 confocal microscope. For distribution analysis, all
imaging was performed at constant confocal settings. Z-stack
images were taken and individual motor neurons selected for
analysis based on an intact nucleus and an intact cell body, as
ascertained by DAPI and ChAT, respectively; motor neurons
were analysed in the plane where the nuclear outline was most
clearly deﬁned. To count the number of VGLUT1 synapses per
ChAT-positive motor neuron soma, Z-stack images were taken
with a slice interval of 0.2mm and a pixel size of 0.08 mm
throughout the whole section thickness to include the whole
cell body (Mentis et al., 2011). Whole DRGs were imaged in a
single plane and selected for imaging and subsequent analysis
based on structural integrity. Only sections that included a full
cross-section through the centre of the DRG were imaged. One
left and one right DRG were imaged per lumbar segment from
L1 and L2 for each mouse. For distribution analysis of sensory
neurons, seven larger area neurons and seven smaller area
neurons were analysed per DRG. All example images of
DRGs are from the L2 segment. Distribution analysis was per-
formed in Fiji using the XOR and measurement functions
(Ferreira and Rasband, 2012) to measure the intensity of the
protein of interest in the nucleus and cytoplasm independent of
each other (Supplementary Fig. 1) (Zhang et al., 2015).
Neuron area was measured by outlining the cell proﬁle
(NF200 or peripherin) in Fiji. Sensory neurons were only ana-
lysed if a clear nuclear outline was observed. The cell counter
plugin in Fiji was used to count NF200- or peripherin-positive
neurons (Sleigh et al., 2017), and to count the number of
VGLUT1 synapses per ChAT-positive soma.
Label-free proteomics
HEK293 cell pellets were lysed in SDT lysis buffer containing
100mM Tris-HCl (pH 7.6; Sigma), 4% (w/v) SDS (VWR).
Protein concentration was determined using a BCA assay
(ThermoScientiﬁc). Aliquots (100 mg) of each HEK293 lysate
were processed through ﬁlter-aided sample preparation invol-
ving buffer exchange to 8M urea and alkylation with 50mM
iodoacetamide. Double digestion with trypsin (Roche, sequen-
cing grade) was then performed, initially for 4 h, then
overnight, at 30C. Samples were desalted by washes with
0.1% triﬂuoroacetic acid and then 70% acetonitrile. Each
sample was separated by injection onto a nanoﬂow LC-MS/
MS Ultimate 3000 RSLC (Thermo Scientiﬁc) system coupled
to a linear ion trap Orbitrap hybrid mass spectrometer (LTQ
Orbitrap Velos Pro, Thermo Scientiﬁc) via a nanoelectrospray
ion source (Thermo Scientiﬁc). Peptides from each digest were
separated with a linear gradient of 2–40% acetonitrile, 0.1%
formic acid over 124min with a constant ﬂow of 300 nl/min.
Full-scan mass spectrometry (MS) survey spectra were
acquired in the LTQ Oribitrap with a resolution of 60 000;
this was followed by IT-MS/MS scans for the 15 most intense
peptide ions. Data were acquired using XcaliburTM software.
Alongside the nine samples, four quality control samples were
processed, each of which consisted of a mixture of the nine
samples.
Proteomic data analysis
Raw proteomic data were imported into Progenesis for ana-
lysis of relative ion abundance and peptide characterization.
The MS/MS output were converted into 2D representations
for each sample; these were then aligned to a quality control
samples with all alignment scores 490%. The data were sub-
sequently ﬁltered where all ions with a charge 45 were
removed, as were features detected 523min and 4137min.
The runs for the different biological replicates of each condi-
tion were combined and statistical P-values were automatically
generated for the peptides in Progenesis software through a
one-way ANOVA on the ArcSinh transform of the normalized
data. The peptides were then ﬁltered and those with a P-value
50.05 or a power40.8 were removed (Supplementary Fig. 1A).
The remaining data were then exported for identiﬁcation of in-
dividual proteins using the IPI-Homo sapiens database via
Mascot Search Engine (V2.3.2) in which 712 proteins were iden-
tiﬁed; statistical analysis was carried out automatically in
Mascot. Proteins identiﬁed in Mascot were then imported into
Progenesis for ﬁltering and further analysis. Peptide conﬂicts
were removed and proteins were ﬁltered to eliminate
those with less than two unique peptides; proteins with a
P-value50.05 or a fold-change 51.1 in either UBA1 overex-
pression compared to control or knockdown compared to con-
trol were removed (Supplementary Fig. 1A). This resulting
dataset contained 222 proteins, which showed the largest signiﬁ-
cant variation in expression following modulation of UBA1 ex-
pression levels (Supplementary Fig. 1B and C). UBA1 itself was
removed from the dataset for all subsequent analysis.
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) was used to identify enriched biological
themes within the ﬁltered proteomics dataset; functional anno-
tation clustering was performed in which enriched terms are
grouped together to identify enriched functional clusters.
Modiﬁed Fischer’s exact P-values for each term are automat-
ically calculated during this analysis; annotation terms that
belong to the same proteins are then grouped together and
assigned an enrichment score, which is the geometric mean
of the P-values for all the terms in that cluster. The enrichment
score is the log10 of the P-value so an enrichment score of
1.3 is equivalent to a P-value of 0.05. This software was also
used to characterize the functions associated with the protein
clusters generated in BioLayout. BioLayout (http://www.
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biolayout.org) was used to identify UBA1-dependent clusters
of proteins based on the expression of the proteins across
UBA1 overexpression, control and UBA1 knockdown. The
network graphs in this study were generated using a Pearson
correlation (set to 0.98) and Markov clustering algorithm
(Enright et al., 2002). The expression proﬁles are displayed
as mean normalized abundance (pareto scale) with standard
error of the mean (SEM) for each condition. Ingenuity path-
way analysis (IPA; www.qiagenbioinformatics.com/products/
ingenuity-pathway-analysis/) was used as previously described
(Wishart et al., 2007). The signiﬁcance of an association be-
tween the dataset and a canonical pathway was deﬁned by a
Fischer’s exact P-value (Savli et al., 2008). A 1.1-fold change
threshold ﬁlter was applied in IPA to each dataset analysed
and only experimentally observed interactions were selected
for each analysis.
Statistical analyses
All statistical analyses were performed in Prism 6 (GraphPad).
Statistical analyses were performed using unpaired two-tailed
Student’s t-test or a one-way ANOVA with a Tukey’s multiple
comparison test for parametric data, and a Mann-Whitney test
or a Kruskal-Wallis test with Dunn’s multiple comparisons test
for non-parametric data, as appropriate. Data are reported as
mean  SEM.
Data availability
Raw proteomics data ﬁles from this study are freely available
for download from http://dx.doi.org/10.7488/ds/2405.
Results
Restoration of UBA1 with
AAV9-UBA1 rescues sensory-motor
connectivity defects in spinal
muscular atrophy mice
To establish whether UBA1-dependent pathways linked to
SMA (Aghamaleky Sarvestany et al., 2014; Hunter et al.,
2014; Wishart et al., 2014; Fuller et al., 2015; Powis et al.,
2016) contribute to the development of defective sensory-
motor connectivity in SMA, we initially investigated the
effects of systemic restoration of UBA1 on sensory-motor
connectivity in SMA mice. Synaptic inputs formed onto
lower motor neurons in the spinal cord were identiﬁed
using immunohistochemical labelling of VGLUT1 (Ling
et al., 2010; Mentis et al., 2011; Fletcher et al., 2017;
Simon et al., 2017). Quantiﬁcation of proprioceptive
inputs onto lower motor neurons in the lumbar region of
spinal cord revealed a signiﬁcant reduction by 34% in
symptomatic (postnatal Day 8) ‘Taiwanese’ SMA mice
compared to littermate controls (Fig. 1A, B and D), con-
ﬁrming previous reports from different mouse models
of SMA (Ling et al., 2010; Mentis et al., 2011). Systemic
restoration of UBA1 levels, via intravenous delivery of
AAV9-UBA1 on the day of birth (Powis et al., 2016), com-
pletely restored the number of VGLUT1-positive synaptic
inputs onto motor neurons in SMA mice (Fig. 1C and D).
Thus, restoration of UBA1 was sufﬁcient to ameliorate de-
fective sensory-motor connectivity in SMA mice, suggesting
that UBA1-dependent pathways play a signiﬁcant role in
the regulation of sensory neuron health in vivo and con-
tribute directly to sensorimotor aspects of disease pathogen-
esis in SMA.
Label-free proteomics identifies
UBA1-dependent proteins
To identify downstream targets of UBA1 likely to be med-
iating its effects on sensory-motor connectivity in SMA,
label-free proteomics was performed on HEK293 cells
where UBA1 had been either overexpressed (using a
UBA1 plasmid) or knocked down (using UBA1 siRNA).
HEK293 cells were chosen for the proteomics screen to
enable dissection of UBA1 dependent pathways relevant
for degeneration in SMA, independent of the reduction in
SMN expression seen in SMA. Western blot conﬁrmed a
10.11-fold increase in levels of UBA1 protein in cells over-
expressing UBA1 (Fig. 2A and B) and a 76% reduction in
UBA1 protein levels in cells transfected with UBA1 siRNA
(Fig. 2A and C). Following ﬁltering of the raw proteomic
data (Supplementary Fig. 2), 222 unique proteins were
identiﬁed with a fold-change 410% after either overex-
pression or knockdown of UBA1. Of the proteins that re-
vealed expression changes, the majority were upregulated
following UBA1 overexpression and conversely downregu-
lated following UBA1 knockdown (Supplementary Fig. 2).
Gene ontology term enrichment analysis was performed
on the ﬁltered proteomic data in DAVID, identifying ami-
noacyl-tRNA synthetases (also known as tRNA ligases),
translation elongation factors, small molecule synthesis,
and protein and RNA transport as signiﬁcantly enriched
gene ontology term clusters with the highest enrichment
scores (Table 1). Gene ontology terms enriched with
lower enrichment score included ubiquitin-like conjugation,
protein complex assembly, and ATP and nucleotide binding
(Table 1); functions related to the ubiquitin conjugation
process. A similar analysis performed in IPA conﬁrmed
RAN signalling (a process involved in nuclear transport)
and tRNA charging (a function of aminoacyl-tRNA
synthetases) as signiﬁcantly enriched canonical pathways.
Nine of the 39 proteins involved in the tRNA
charging canonical pathway were present in this dataset
(Supplementary Table 1).
To identify speciﬁc UBA1 target proteins, BioLayout ana-
lyses were performed whereby clusters of proteins were
generated based on the similarity of protein expression pro-
ﬁles. This analysis revealed two main groups of proteins
modiﬁed downstream of UBA1, each of which was further
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subdivided, generating six subclusters of proteins (Fig. 2D).
Two of the clusters (clusters 1 and 4) showed UBA1-de-
pendent expression proﬁles (Fig. 2E and F), while the other
four clusters showed a prominent expression change in
only one experimental condition (Supplementary Fig. 3).
The ﬁrst UBA1-dependent cluster of proteins, cluster 1,
contained proteins that were upregulated following UBA1
overexpression and downregulated following UBA1 knock-
down (Fig. 2E). Subsequent analysis in DAVID revealed
that the proteins in this cluster function as aminoacyl-
tRNA synthetases or in glycolysis, translation elongation
or assembly of protein complexes. Cluster 4 showed the
opposite UBA1-dependent expression proﬁle (downregula-
tion following UBA1 overexpression and upregulations fol-
lowing UBA1 knockdown; Fig. 2F) in which proteins
function in transport and localization of protein, RNA
and nucleic acids. Interestingly, the functions of the
UBA1-dependent clusters overlap with the enriched gene
ontology terms and canonical pathways (Table 1 and
Supplementary Table 1); thus, indicating that these are
key protein families and functions changed on modulation
of UBA1 protein levels.
To investigate UBA1 dependency at the level of individ-
ual proteins and interaction networks, a network analysis
was performed using IPA software. Interestingly, the top
protein network generated for each condition (overexpres-
sion or knockdown of UBA1) was composed of the same
proteins, in which 25 of 30 proteins present in the network
behaved in a UBA1-dependent manner (Fig. 2G and H; see
Supplementary Figs 4 and 5 for expanded networks), sug-
gesting that modulation of UBA1 expression causes wide-
spread reciprocal changes in expression in discrete
networks of proteins.
Importantly, our analyses repeatedly highlighted aminoa-
cyl-tRNA synthetases (including GARS, YARS, HARS and
WARS) as key UBA1 downstream targets (Fig. 2G and H).
This ﬁnding was of particular interest and relevance due to
known links between this family of enzymes and neurode-
generative conditions, with mutations in several of these
genes causing hereditary neuropathies (Kapur et al.,
2017). More speciﬁcally, the GlyRS protein (GARS)
encoded by GARS was of particular interest because of
its known role in Charcot-Marie-Tooth disease type 2D
(CMT2D), a neuromuscular disorder with phenotypic
Figure 1 Rescue of sensory-motor connectivity defects in the spinal cord of SMA mice following systemic restoration of
UBA1. (A–C) Lumbar motor neurons from control, SMA and SMA + AAV9-UBA1 mice labelled with ChAT (magenta), VGLUT1 (green) and
DAPI. Scale bar = 10mm. (D) Quantification of the number of VGLUT1 synapses per ChAT-positive motor neuron soma. n = 3 mice per condition,
n4 20 motor neurons analysed per mouse. ns = not significant, *P5 0.05.
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similarity to SMA (Antonellis et al., 2003; Sivakumar et al.,
2005; James et al., 2006; Motley et al., 2010).
UBA1 regulates GARS expression
independent of its role in
ubiquitylation
As the canonical role of UBA1 concerns priming of the
ubiquitylation cascade (Groen and Gillingwater, 2015),
we next sought to investigate whether the downstream pro-
tein targets of UBA1 identiﬁed in our proteomics screen
were showing different levels of expression due to direct
perturbations in their ubiquitylation status. To investigate
the effect of UBA1 modulation on overall ubiquitylation
levels, HEK293 cells were transfected with ubiquitin (Ub-
HA) and a UBA1 plasmid, UBA1 siRNA or a suitable
control vector. As expected, following overexpression of
UBA1 overall polyubiquitylation of substrate proteins was
Figure 2 Label-free proteomics analysis identifies tRNA synthetases as UBA1-dependent proteins. (A) UBA1 expression in
HEK293 cells used for proteomics screen showing UBA1 overexpression (OE) and knockdown (KD) compared to control. CoxIV and
H3 = loading control. (B and C) Quantification of UBA1 overexpression (B) and knockdown (C). Ctrl = control; **P5 0.01, ***P5 0.001.
(D) BioLayout clustering 3D representation of proteomic expression across UBA1 overexpression, control and UBA1 knockdown. Nodes
represent proteins and edges represent similarity of expression between proteins and clusters of proteins with similar expression profiles
are indicated by different colours. Cluster numbers are indicated. (E and F) Expression profile means  SEM in log scale for the two
UBA1-dependent clusters: cluster 1 (E) and cluster 4 (F). (G and H) IPA analysis showing the top network for UBA1 overexpression/control
(G) and UBA1 knockdown/control (H), proteins highlighted in magenta are upregulated, proteins highlighted in green are downregulated. See also
Supplementary Figs 2–5 and Supplementary Table 1.
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increased (Fig. 3A). Following UBA1 knockdown, there
was a concomitant, albeit less prominent, change in overall
ubiquitylation status with a modest reduction in polyubi-
quitylation of substrate proteins (Fig. 3B). Overall, this con-
ﬁrms that modulation of UBA1 levels leads to changes in
ubiquitylation of substrate proteins, demonstrating that
UBA1 can inﬂuence the expression of downstream targets
through differential ubiquitylation.
To investigate whether the UBA1-dependent tRNA-synthe-
tase GARS was being differentially ubiquitylated following
modulation of UBA1 expression, a protein-speciﬁc ubiquity-
lation assay was performed. As the ubiquitylation pattern of
SMN is well characterized (Chang et al., 2004; Kwon et al.,
2013; Abera et al., 2016), the ubiquitylation assay, in which
the proteins of interest were co-transfected, was initially opti-
mized using SMN, conﬁrming the ubiquitylation pattern of
SMN (Supplementary Fig. 6). Surprisingly, following over-
expression of UBA1, in the presence of both GARS and
ubiquitin, there was no change in the overall ubiquitylation
of GARS (Fig. 3C). Similarly, following UBA1 knockdown,
there was also no change in the ubiquitylation of GARS
compared to control UBA1 expression (Fig. 3D). Thus,
modulation of UBA1 expression did not affect the ubiquity-
lation of GARS, suggesting that UBA1 inﬂuences the expres-
sion of GARS through a non-canonical pathway
independent of its role in the ubiquitylation cascade.
Perturbations in UBA1 lead to
disruption of GARS in spinal
muscular atrophy mice
To explore the potential role and relevance of the UBA1/
GARS pathway in SMA pathogenesis further, we next
wanted to establish whether GARS protein was disrupted
in SMA in vivo. Furthermore, to investigate the wider
effects of UBA1 on tRNA synthetases, we quantiﬁed the
expression of the tRNA-synthetase YARS in SMA mice;
mutations in YARS cause dominant intermediate CMT
type C (DI-CMTC) (Jordanova et al., 2006). Importantly,
it has previously been demonstrated that both UBA1 and
SMN expression are reduced in spinal cord from
Taiwanese SMA mice (Powis et al., 2016; Groen et al.,
2018a). GARS showed an increase of 100% in spinal
cord from SMA mice at postnatal Day 8 compared to con-
trol littermates (Fig. 4A and B) whilst YARS showed a
reduction of 37% in SMA spinal cord (Supplementary
Fig. 7A and B); thereby validating expression changes in
two different tRNA-synthetases in SMA.
Interestingly, however, there was no signiﬁcant difference
in GARS expression speciﬁcally within lower motor neuron
bodies in the spinal cord (Supplementary Fig. 8A and B),
suggesting that modulations in UBA1/GARS pathways are
unlikely to underlie motor neuron pathology in SMA. In
stark contrast, expression changes of GARS were present in
the dorsal root ganglia (DRG), which contain sensory neuron
bodies (Fig. 4C and D). As protein levels of SMN and UBA1
have not previously been reported for DRGs in control and
SMA mice, their expression was quantiﬁed by western blot
analysis. As expected, a signiﬁcant reduction of SMN was
observed in DRGs (Fig. 4C) with an overall reduction of
92% in SMA mice compared to controls (Fig. 4D). This is
consistent with the reduction of SMN protein reported in
SMA patients (Lefebvre et al., 1997) and the reduced levels
of Smn transcript reported in DRGs from ‘delta7’ SMA mice
(Mentis et al., 2011). Similarly, UBA1 was reduced by 28%
in late-symptomatic SMA DRGs compared to controls (Fig.
4C and D), consistent with the magnitude of UBA1 reduction
reported in spinal cord from late-symptomatic Taiwanese
SMA mice (Powis et al., 2016). Consistent with the change
in expression seen in spinal cord, GARS expression was upre-
gulated by 56% in SMA DRGs compared to controls (Fig.
4C and D), while YARS expression showed no change in
SMA DRGs (Supplementary Fig. 7A and B). Thus, suppres-
sion of UBA1 downstream of SMN leads to a signiﬁcant
increase in GARS protein levels in SMA mice in vivo, with
DRGs being particularly affected.
Identification of a sensory neuron fate
phenotype in spinal muscular atrophy
mice
The increased levels of GARS we observed in SMA were
consistent with changes in GARS protein levels reported in
CMT2D, where they are notably increased during neonatal
development and disease progression (Achilli et al., 2009;
Motley et al., 2010, 2011). It has recently been shown that
disruption to sensory neuron fate is a signiﬁcant feature of
disease pathogenesis in CMT2D mice, leading to an alter-
ation in the functional subpopulations of sensory neurons
in the DRG (Sleigh et al., 2017). We therefore wanted to
establish whether similar GARS-dependent phenotypes
Table 1 Gene ontology term enrichment of proteins
changed following modulation of UBA1 expression
GO term cluster Enrichment
score
Translation elongation 4.56
tRNA ligase activity 4.31
Nucleic acid synthesis 4.10
Cytoskeleton 3.30
Protein transport and localisation 3.03
RNA transport and localisation 2.95
Protein complex assembly 2.85
ATP and nucleotide binding 2.55
Glycolysis 2.45
Cytoskeletal binding 2.36
Ubl conjugation 2.25
Membrane bound vesicle 2.04
GTPase binding 2.02
See also Supplementary Table 1.
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were contributing to the sensory-motor connectivity defects
that occur in SMA.
Large area sensory neurons within DRGs are predomin-
antly either mechanoreceptors (sense touch) or propriocep-
tors (sense position and movement), both of which stain
positive for NF200: 20% of NF200-positive neurons
are proprioceptors and the remaining 80% are mechano-
receptors (Sleigh et al., 2017). Smaller area sensory neurons
stain positive for peripherin and are mostly nociceptive. In
CMT2D mice there is a severity-dependent disruption to
the fate of sensory neurons, with a decrease in the percent-
age of NF200-positive neurons and an increase in the per-
centage of peripherin-positive neurons, leading to
concordant behavioural deﬁcits (Sleigh et al., 2017).
Qualitatively, DRGs from SMA mice appeared smaller
with fewer NF200-positive neurons compared to control
Figure 3 UBA1 influences GARS expression through a non-canonical function. (A and B) HEK293 cells were transfected with
ubiquitin-HA (Ub-HA) and UBA1 (A) or UBA1 siRNA (B); western blot of UBA1 and ubiquitin (immunoblotted for HA tag), showing poly-
ubiquitylated substrate proteins (Poly-Ub), and free triubiquitin (Tri-Ub), diubiquitin (Di-Ub) and monoubiquitin (Mono-Ub). (C and D) HEK293
cells were transfected with GARS-GFP or GFP along with Ub-HA and UBA1 (C) or UBA1 siRNA (D). Input control samples were immunoblotted
for UBA1 and GARS; immunoprecipitation (IP) with GFP; IP samples were immunoblotted for GFP and HA. IgG bands and polyubiquitylation
(Poly-Ub) smears are indicated. High intensity immunoblots show polyubiquitylation smears imaged at increased laser power. See also
Supplementary Fig. 6.
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mice (Fig. 5A and B). Quantiﬁcation revealed a signiﬁcant
24% reduction in the percentage of NF200-positive neu-
rons relative to control (Fig. 5B), with a concomitant in-
crease in peripherin-positive neurons by 85% relative to
control (Fig. 5C). CMT2D mice have a reduction in the
area of sensory neuron cell bodies (Sleigh et al., 2017).
Likewise, NF200-positive neurons were signiﬁcantly smaller
in SMA mice than in controls, with an average reduction of
101mm2 per neuron (Fig. 5D). Similarly, peripherin-positive
neurons were also signiﬁcantly smaller in SMA mice
(Fig. 5E), thereby conﬁrming that SMA DRGs were
indeed smaller than those in control animals, as has previ-
ously been reported for other organs in SMA (Powis et al.,
2016; Thomson et al., 2017; Maxwell et al., 2018). Despite
the overall reduced size and disruption to sensory neuron
fate in SMA DRGs, these phenotypes were not due to overt
cell death in the SMA DRGs (Supplementary Fig. 9), a
ﬁnding consistent with previous reports in CMT2D
(Sleigh et al., 2017).
Because of the identiﬁcation of a reduction in the pro-
portions of NF200-positive sensory neurons in SMA, we
next wanted to investigate whether mechanoreceptors and
proprioceptors were differentially affected. Quantiﬁcation
of the overall percentage of sensory neurons that stain posi-
tive for parvalbumin, a proprioceptor speciﬁc marker, re-
vealed no signiﬁcant difference in the proportion of
parvalbumin-positive sensory neurons in SMA DRGs com-
pared to control (Fig. 5F and G). This is consistent with a
previous report in a different mouse model of SMA (Mentis
et al., 2011), and demonstrated that, as in CMT2D (Sleigh
et al., 2017), both subtypes of NF200-positive sensory
neurons were equally affected leading to the disruption to
sensory neuron fate seen in SMA.
Taken together, these ﬁndings reveal a novel sensory neuron
fate phenotype associated with increased levels of GARS in
SMA mice, highlighting signiﬁcant pathological overlap be-
tween SMA and CMT2D at the level of sensory neurons.
Dysregulation of UBA1/
GARS-dependent pathways in
sensory neurons from spinal
muscular atrophy mice
To investigate links between UBA1/GARS-dependent path-
ways and disrupted sensory neuron fate in SMA further,
the ratio of UBA1 and GARS expression was investigated
at the level of individual sensory neurons within the DRG.
There was less prominent nuclear labelling and more pro-
nounced cytoplasmic labelling of UBA1 in DRGs from
SMA mice, indicating a shift in the subcellular distribution
of UBA1 (Fig. 6A). Quantiﬁcation revealed a signiﬁcant
reduction of the nuclear-cytoplasmic ratio (NCR) by 24%
in SMA mice compared to controls (control = 5.34,
SMA = 4.07; Fig. 6B). Sensory neurons also showed a sig-
niﬁcant increase in the NCR of GARS in SMA compared to
controls (Fig. 6C and D). Notably, however, larger diam-
eter neurons revealed a selective increase in the intensity of
GARS labelling (Fig. 6C). Interestingly, here changes in
GARS expression occurred in the opposite direction to
changes in UBA1 expression, consistent with changes at
the whole tissue level as detected by western blot analysis
Figure 4 GARS is dysregulated in neuronal tissue from SMA mice. (A and B) Western blot (A) and quantification (B) of GARS
protein levels in spinal cord from late-symptomatic SMA mice and control littermates. a-Tubulin (a-Tub) = loading control. (C and D)
Western blot (C) and quantification (D) of SMN, UBA1 and GARS protein levels in DRG from late-symptomatic SMA mice and control
littermates. a-Tubulin (a-Tub), total protein (Ponceau): loading controls. n = 3 mice per condition. See also Supplementary Figs 7 and 8.
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of whole DRGs and spinal cord (Fig. 4). Thus, sensory
neuron cell fate phenotypes observed in SMA mice correl-
ate directly with parallel expression changes in key proteins
of the UBA1/GARS pathway.
Restoration of UBA1 rescues sensory
neuron fate phenotypes in spinal
muscular atrophy mice
Finally, we wanted to establish whether the rescue of sen-
sory-motor connectivity observed in the spinal cord of
SMA mice treated with AAV9-UBA1 was due to correction
of sensory neuron fate phenotypes in the DRG and if this
disruption to sensory neuron fate in SMA mice was directly
dependent on changes in the UBA1/GARS pathway.
Quantitative western blot performed on lumbar DRGs
from FVB mice and FVB mice injected with AAV9-UBA1
conﬁrmed transduction of DRG sensory neurons, with an
increase in UBA1 expression by 33% in mice injected with
AAV9-UBA1, but no change in SMN expression
(Supplementary Fig. 10A and B). Immunoﬂuorescence con-
ﬁrmed transduction of sensory neurons at the cellular level
Figure 5 Sensory neuron fate is disrupted in SMA dorsal root ganglia. (A) Spinal column sections from lumbar segments 1 and 2 of
late-symptomatic SMA and control mice labelled with NF200 (magenta) and peripherin (green). DRG are outlined in the top panels, boxes indicate
the area in bottom panel. Nuclei of cells in bottom panels are labelled with DAPI. N = NF200-positive neurons; P = peripherin-positive neurons.
Scale bars = 100 mm (top), 10 mm (bottom). (B and C) Quantification of the percentage of NF200-positive (NF200+ ) (B) and peripherin-positive
(peripherin+ ) (C) sensory neurons. n = 3 mice per condition, n = 4 DRGs per mouse. (D and E) Quantification of the area of NF200 + (D) and
peripherin+ (E) sensory neurons. n = 3 mice per condition, n = 2 DRGs per mouse (seven NF200+ and seven peripherin+ neurons per DRG were
analysed). (F) Spinal column sections from lumbar segments 1 and 2 of late-symptomatic SMA and control mice labelled with parvalbumin (white),
beta-III tubulin (green) and DAPI (blue), dorsal root ganglia (DRG) are outlined. Scale bar = 100 mm. (G) Quantification of parvalbumin-positive
sensory neurons as a percentage of beta-III tubulin-positive sensory neurons. n = 3 mice per condition, n = 4 DRGs per mouse. *P5 0.05,
**P5 0.01. See also Supplementary Fig. 9.
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(Supplementary Fig. 10C). Similarly, SMA mice and SMA
mice injected with AAV9-UBA1 revealed a signiﬁcant in-
crease in UBA1 levels, by 17% compared to non-injected
animals at postnatal Day 8, but no change in SMN expres-
sion (Fig. 7A and B). Upregulation of UBA1 was also evi-
dent at the cellular level within individual sensory neurons
Figure 6 Dysregulation of UBA1 and GARS in dorsal root ganglia sensory neurons from SMA mice. (A and C) Spinal column
sections from lumbar segments 1 and 2 of late-symptomatic SMA and control mice labelled with UBA1a (A) or GARS (C) (green), SMI32
(magenta) and DAPI. DRG are outlined in overview panels, boxes indicate the area in lower panels. Arrows in bottom panel indicate sensory neurons
with altered UBA1 (A) or GARS (C) expression. N = NF200-positive neurons; P = peripherin-positive neurons. Scale bars = 100 mm (overview),
10 mm (lower panels). (B and D) Late-symptomatic SMA DRG sensory neurons show a reduction in the nuclear to cytoplasmic ratio of UBA1
(B) and an increase in the nuclear to cytoplasmic ratio of GARS (D) compared to control mice. n = 3 mice per condition, n = 4 DRGs per mouse
(14 sensory neurons were analysed per DRG); *P5 0.05, ***P4 0.001.
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of the DRG (Fig. 7C). Importantly, upregulation of UBA1
using AAV9-UBA1 reduced GARS levels by 29% (Fig. 7A
and B), back toward the levels observed in DRGs from
control mice.
To determine whether AAV9-UBA1-mediated correction
of GARS levels rescued sensory neuron fate phenotypes, we
assessed sensory neuron subtype proportions in SMA mice
and SMA mice injected with AAV9-UBA1. Overexpression
Figure 7 Restoration of UBA1 in SMA mice reverses GARS dysregulation and rescues sensory neuron cell fate phenotypes.
(A and B) Representative fluorescent western blot (A) and quantification (B) of SMN, UBA1 and GARS in dorsal root ganglia from late-
symptomatic SMA mice and SMA mice injected with AAV9-UBA1 (SMA + AAV9-UBA1). a-Tubulin (a-Tub): loading control. n = 3 mice per
condition. (C) Spinal column sections from lumbar segments 1 and 2 of late-symptomatic SMA and SMA + AAV9-UBA1 mice labelled with UBA1a
(green), SMI32 (magenta) and DAPI. (D) Spinal column sections from lumbar segments 1 and 2 of late-symptomatic SMA and SMA + AAV9-UBA1
mice labelled with NF200 (magenta) and peripherin (green). (C and D) Dorsal root ganglia (DRG) are outlined. (E and F) Quantification of the
percentage of NF200-positive (NF200+ ) (E) and peripherin-positive (peripherin+ ) (F) sensory neurons. Data from control mice is shown as
reference. n = 3 mice per condition, n = 4 DRGs per mouse. (G and H) Quantification of the area of NF200 + (G) and peripherin+ (H) sensory
neurons. n = 3 mice per condition, n = 2 DRGs per mouse (seven NF200+ and seven peripherin+ neurons per DRG were analysed); ns = not
significant. *P5 0.05, **P5 0.01. See also Supplementary Fig. 10 and 11.
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of UBA1 in SMA mice fully rescued the disruption to sen-
sory neuron fate (Fig. 7D) whereby the percentage of
NF200-positive neurons was increased by 46% in SMA
mice injected with AAV9-UBA1 relative to SMA mice
(Fig. 7E). There was also a signiﬁcant reduction in the per-
centage of peripherin-positive neurons in SMA mice in-
jected with AAV9-UBA1 by 9% relative to SMA mice
(Fig. 7F). Compared to data obtained from control mice,
there was no signiﬁcant difference in the percentage of
NF200- or peripherin-positive neurons in SMA mice trea-
ted with AAV9-UBA1 (Fig. 7E and F). Interestingly, follow-
ing treatment with AAV9-UBA1 in SMA mice there was a
signiﬁcant increase in the percentage of parvalbumin-posi-
tive neurons, from 8% of the total sensory neuron popu-
lation in SMA mice, to 13% in SMA mice injected with
AAV9-UBA1 (Supplementary Fig. 11A and B). This indi-
cates that AAV9-UBA1 predominantly affects propriocep-
tive sensory neurons.
Overexpression of UBA1 in SMA mice also rescued the
area of sensory neurons with an increase in the area of
NF200-positive neurons by an average of 129 mm2 per
neuron (Fig. 7G) and an increase in peripherin-positive
neuron area by an average of 40 mm2 in treated SMA
mice (Fig. 7H). Thus, restoration of UBA1 levels using
viral gene delivery in SMA mice was sufﬁcient to correct
GARS protein levels in sensory neurons and fully rescue the
disruption to sensory neuron fate.
Discussion
Taken together, data from the current study demonstrate
that UBA1 is a major regulator of sensory-motor connect-
ivity phenotypes in SMA. Aminoacyl-tRNA synthetases
were identiﬁed as key UBA1 downstream targets, revealing
a novel UBA1/GARS dependent pathway that mediates sen-
sory neuron cell fate through a non-canonical pathway dis-
tinct from differential ubiquitylation. Restoration of UBA1
in SMA mice using a gene therapy approach revealed that
correction of UBA1 levels, and downstream UBA1/GARS
pathways, was sufﬁcient to rescue sensory neuron cell fate
phenotypes, and sensory-motor connectivity defects in the
spinal cord, in SMA mice (Supplementary Fig. 12). Because
of the known role of mutant GARS in mediating sensory
neuron pathology in CMT2D, our ﬁndings provide experi-
mental evidence of a signiﬁcant molecular and phenotypic
overlap between SMA and CMT.
The ﬁnding that the newly-identiﬁed UBA1/GARS path-
way was regulated independently of the ubiquitylation
status of GARS adds further support to a growing body
of evidence suggesting that UBA1 can inﬂuence its down-
stream targets and pathways through non-canonical func-
tions. For example, functions of UBA1 outside of the
canonical ubiquitylation cascade have previously been re-
ported in Atg8-dependent autophagy (Chang et al., 2013).
Our ﬁndings therefore extend our understanding of the
broad range of pathways inﬂuenced by UBA1, and conﬁrm
the existence of multiple, non-canonical functions for UBA1
in vivo. Consistent with this model, recent studies have
suggested that UBA6 ubiquitylates a larger proportion of
the proteome than previously thought and indicated that
ubiquitylation of GARS may be performed by UBA6 (Liu
et al., 2017b).
Moreover, the tissue-speciﬁc nature of UBA1-dependent
perturbations in GARS and YARS identiﬁed here echoes
previous work in which downstream molecular targets of
UBA1 were found to vary depending on the tissue and
organ being examined (Wishart et al., 2014). For example,
therapies treating the accumulation of b-catenin down-
stream of UBA1 in SMA, rescued neuromuscular but not
systemic/non-neuromuscular pathologies in Taiwanese
SMA mice (Wishart et al., 2014). Furthermore, it has pre-
viously shown that AAV9-UBA1 increases SMN expression
in hearts from both SMA and control mice compared to
untreated SMA and control mice, respectively (Powis et al.,
2016). Here, we report that AAV9-UBA1 does not increase
SMN expression in either SMA (Fig. 7A and B) or control
DRGs (Supplementary Fig. 10A and B), indicating that
modest SMN restoration may contribute to the rescue of
some SMA phenotypes, but not the restoration of sensory
neuron phenotypes following AAV9-UBA1 treatment. This
suggests that therapies restoring UBA1, which lead to wide-
spread rescue of SMA phenotypes (Powis et al., 2016), are
likely to be modulating numerous, tissue-speciﬁc down-
stream pathways of UBA1, thereby revealing a complex
spatiotemporal inﬂuence of ubiquitin pathways on disease
pathogenesis in SMA and related conditions.
While sensory neuron pathology has previously been
identiﬁed in models of SMA (Jablonka et al., 2006; Ling
et al., 2010; Mentis et al., 2011; Fletcher et al., 2017), the
disruption to sensory neuron fate and reduction in the size
of sensory neurons within the DRG reported here provides
important insights into the pathogenesis of sensory-motor
connectivity defects in SMA. A recent study suggested that
motor neuron hyperexcitability in SMA occurs speciﬁcally
due to defects in proprioceptive sensory neurons, with the
onset of motor neuron dysfunction correlating with sen-
sory-motor connectivity defects in SMA. Importantly,
blocking neurotransmission speciﬁcally in proprioceptive
neurons in wild-type mice caused severe motor defects,
shortened lifespan and rendered motor neurons dysfunc-
tional (Fletcher et al., 2017). Together this suggests that
restoration of proprioceptive synapses in SMA leads to
increased functionality of motor neurons. Our ﬁnding
that defects in sensory neuron fate speciﬁcally target
NF200-positive neurons in SMA, and that restoration of
UBA1 was sufﬁcient to rescue sensory neuron fate in the
DRG alongside sensory-motor connectivity in the spinal
cord, suggests that UBA1/GARS-dependent regulation of
this sensory neuron subtype plays a critical role in the
pathogenesis of both motor and sensory phenotypes in
SMA. It also highlights the possibility that UBA1/GARS-
mediated restoration of sensory-motor connectivity leads
to improvements in motor neuron function which, along
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with rescue of other motor neuron and muscle speciﬁc de-
fects through alternative UBA1-mediated pathways, cause
the phenotypic improvements in neuromuscular pathology
previously reported in AAV9-UBA1 treated SMA mice
(Powis et al., 2016).
Importantly, sensory pathology in SMA patients is
becoming increasingly well characterized (Supplementary
Table 2). Several reports of patients with SMA type 1 in-
dicate abnormal sensory conduction (Duman et al., 2013)
or absence of sensory responses (Reid et al., 2016), as well
as axonal degeneration in sensory nerves (Rudnik-
Schoneborn et al., 2003). In earlier studies of presumed
SMA cases, axonal degeneration of sensory neurons was
also identiﬁed, alongside ballooned neurons and chromato-
lysis within DRGs (Marshall and Duchen, 1975; Carpenter
et al., 1978; Murayama et al., 1991). Furthermore, a gen-
etically-conﬁrmed case of XL-SMA showed nodules within
the DRG, indicating a loss of sensory neurons
(Supplementary Table 2) (Dlamini et al., 2013).
Our ﬁnding of a key role for GARS in regulating sensory
neuron phenotypes and sensory-motor connectivity in SMA,
provides experimental support for the hypothesis that there
is signiﬁcant molecular and phenotypic overlap between
SMA and CMT2D. Furthermore, the ﬁnding of altered
YARS expression in SMA spinal cord indicates a wider over-
lap of spinal muscular atrophies and peripheral neuropa-
thies. Interestingly, several cases of co-segregation of SMA
and CMT have been reported (Supplementary Table 2)
(Jedrzejowska et al., 2008; Fernandez et al., 2016), indicat-
ing that the pathologies of these two diseases can occur
simultaneously. In addition to this, several genes have now
been identiﬁed where mutations can cause a range of pheno-
types incorporating both CMT and SMA-like diseases.
GARS is one such gene, where mutations can cause
CMT2D, distal-SMA type V or more classical infantile
SMA (Supplementary Table 2) (Antonellis et al., 2003;
James et al., 2006; Eskuri et al., 2012). Similarly, mutations
in MORC2 can cause CMT type 2Z or SMA (Schottmann
et al., 2016; Sevilla et al., 2016) and mutations in
IGHMBP2 have been shown to cause both CMT type 2S
and SMA with respiratory distress type 1 (SMARD1;
Supplementary Table 2) (Grohmann et al., 2001; Cottenie
et al., 2014; Pedurupillay et al., 2016; Liu et al., 2017a).
Moreover, mutations in LRSAM1, an E3 ubiquitin ligase,
cause CMT type 2G (Peeters et al., 2016) thereby implicat-
ing ubiquitin pathways in the pathogenesis of CMT.
Similarly, mutations in PIEZO2, which encodes a mechan-
osensitive ion channel responsible for mechanosensation of
light touch and proprioception, can cause a neuromuscular
disease characterized by muscle atrophy, mild sensory in-
volvement, delayed motor milestones and scoliosis (Chesler
et al., 2016; Delle Vedove et al., 2016); suggesting that de-
fects within sensory neurons themselves can lead to muscle
defects and delayed motor development. Together, not only
does this highlight considerable overlap between the pheno-
types of CMT and SMA, but it also demonstrates consider-
able overlap of genetic pathways and molecular causes of
these diseases, hinting at the potential of shared therapeutic
opportunities for these neuromuscular conditions.
Acknowledgements
The authors thank Elena Perenthaler for help with optimis-
ing the ubiquitylation assay and other members of the
Gillingwater laboratory and Natalie Courtney for valuable
input and discussion. The authors also thank the IMPACT
facility at the University of Edinburgh.
Funding
This work was supported by funding from the Euan
MacDonald Centre for Motor Neurone Disease Research,
SMA Europe, the SMA Trust UK Consortium (all to
T.H.G.), the Wellcome Trust (to J.N.S., E.J.N.G and
T.H.G), the Darwin foundation and the BBSRC (to
T.M.W), the European Union’s Horizon 2020 Research
and Innovation programme under grant agreement 739572,
the Wellcome Trust Senior Investigator Award (107116/Z/
15/Z) and a UK Dementia Research Institute Foundation
award (all to G.S.).
Competing interests
T.H.G. is Chair of the Scientiﬁc and Clinical Advisory
Board of the SMA Trust.
Supplementary material
Supplementary material is available at Brain online.
References
Abera MB, Xiao J, Nofziger J, Titus S, Southall N, Zheng W, et al.
ML372 blocks SMN ubiquitination and improves spinal muscular
atrophy pathology in mice. JCI Insight 2016; 1: e88427.
Achilli F, Bros-Facer V, Williams HP, Banks GT, AlQatari M, Chia R,
et al. An ENU-induced mutation in mouse glycyl-tRNA synthetase
(GARS) causes peripheral sensory and motor phenotypes creating a
model of Charcot-Marie-Tooth type 2D peripheral neuropathy. Dis
Model Mech 2009; 2: 359–73.
Aghamaleky Sarvestany A, Hunter G, Tavendale A, Lamont DJ,
Llavero Hurtado M, Graham LC, et al. Label-free quantitative
proteomic proﬁling identiﬁes disruption of ubiquitin homeostasis
as a key driver of Schwann cell defects in spinal muscular atrophy.
J Proteome Res 2014; 13: 4546–57.
Antonellis A, Ellsworth RE, Sambuughin N, Puls I, Abel A, Lee-Lin
SQ, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-
Tooth disease type 2D and distal spinal muscular atrophy type V.
Am J Hum Genet 2003; 72: 1293–9.
Balak CD, Hunter JM, Ahearn ME, Wiley D, D’Urso G, Baumbach-
Reardon L. Functional characterizations of rare UBA1 variants in
X-linked spinal muscular atrophy. F1000Res 2017; 6: 1636.
UBA1/GARS-dependent pathology in SMA BRAIN 2018: Page 15 of 17 | 15
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
y237/5104293 by Library - D
uncan of Jordanstone user on 24 Septem
ber 2018
Carpenter S, Karpati G, Rothman S, Watters G, Andermann F.
Pathological involvement of primary sensory neurons in Werdnig-
Hoffmann disease. Acta Neuropathol 1978; 42: 91–7.
Chang HC, Hung WC, Chuang YJ, Jong YJ. Degradation of Survival
Motor Neuron (SMN) protein is mediated via the ubiquitin/prote-
asome pathway. Neurochem Int 2004; 45: 1107–12.
Chang TK, Shravage BV, Hayes SD, Powers CM, Simin RT, Wade
Harper J, et al. Uba1 functions in Atg7- and Atg3-independent
autophagy. Nat Cell Biol 2013; 15: 1067–78.
Chesler AT, Szczot M, Bharucha-Goebel D, Ceko M, Donkervoort S,
Laubacher C, et al. The role of PIEZO2 in human mechanosensa-
tion. N Engl J Med 2016; 375: 1355–64.
Cottenie E, Kochanski A, Jordanova A, Bansagi B, Zimon M, Horga
A, et al. Truncating and missense mutations in IGHMBP2 cause
Charcot-Marie Tooth disease type 2. Am J Hum Genet 2014; 95:
590–601.
Delle Vedove A, Storbeck M, Heller R, Holker I, Hebbar M, Shukla
A, et al. Biallelic loss of proprioception-related PIEZO2 causes mus-
cular atrophy with perinatal respiratory distress, arthrogryposis, and
scoliosis. Am J Hum Genet 2016; 99: 1206–16.
Dlamini N, Josifova DJ, Paine SM, Wraige E, Pitt M, Murphy AJ,
et al. Clinical and neuropathological features of X-linked spinal
muscular atrophy (SMAX2) associated with a novel mutation in
the UBA1 gene. Neuromuscul Disord 2013; 23: 391–8.
Duman O, Uysal H, Skjei KL, Kizilay F, Karauzum S, Haspolat S.
Sensorimotor polyneuropathy in patients with SMA type-1: electro-
neuromyographic ﬁndings. Muscle Nerve 2013; 48: 117–21.
Enright AJ, Van Dongen S, Ouzounis CA. An efﬁcient algorithm for
large-scale detection of protein families. Nucleic Acids Res 2002; 30:
1575–84.
Eskuri JM, Stanley CM, Moore SA, Mathews KD. Infantile onset
CMT2D/dSMA V in monozygotic twins due to a mutation in the
anticodon-binding domain of GARS. J Peripher Nerv Syst 2012; 17:
132–4.
Fernandez RM, Pecina A, Munoz-Cabello B, Antinolo G, Borrego S.
Co-segregation of a homozygous SMN1 deletion and a heterozygous
PMP22 duplication in a patient. Clin Case Rep 2016; 4: 879–84.
Ferreira T, Rasband W. ImageJ user guide—IJ 1.46r. 2012. Available
from: https://imagej.nih.gov/ij/docs/guide/146–30.html.
Fletcher EV, Simon CM, Pagiazitis JG, Chalif JI, Vukojicic A, Drobac
E, et al. Reduced sensory synaptic excitation impairs motor neuron
function via Kv2.1 in spinal muscular atrophy. Nat Neurosci 2017;
20: 905–16.
Fuller HR, Mandefro B, Shirran SL, Gross AR, Kaus AS, Botting CH,
et al. Spinal muscular atrophy patient iPSC-Derived motor neurons
have reduced expression of proteins important in neuronal develop-
ment. Front Cell Neurosci 2015; 9: 506.
Groen EJN, Gillingwater TH. UBA1: at the crossroads of ubiquitin
homeostasis and neurodegeneration. Trends Mol Med 2015; 21:
622–32.
Groen EJN, Perenthaler E, Courtney NL, Jordan CY, Shorrock HK,
van der Hoorn D, et al. Temporal and tissue-speciﬁc variability of
SMN protein levels in mouse models of spinal muscular atrophy.
Hum Mol Genet 2018a; 27: 2851–62.
Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for
spinal muscular atrophy: promises and challenges. Nat Rev Neurol
2018b 14, 214–24.
Grohmann K, Schuelke M, Diers A, Hoffmann K, Lucke B, Adams C,
et al. Mutations in the gene encoding immunoglobulin mu-binding
protein 2 cause spinal muscular atrophy with respiratory distress
type 1. Nat Genet 2001; 29: 75–7.
Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH,
et al. A mouse model for spinal muscular atrophy. Nat Genet 2000;
24: 66–70.
Hunter G, Aghamaleky Sarvestany A, Roche SL, Symes RC,
Gillingwater TH. SMN-dependent intrinsic defects in Schwann
cells in mouse models of spinal muscular atrophy. Hum Mol
Genet 2014; 23: 2235–50.
Jablonka S, Karle K, Sandner B, Andreassi C, von Au K, Sendtner M.
Distinct and overlapping alterations in motor and sensory neurons
in a mouse model of spinal muscular atrophy. Hum Mol Genet
2006; 15: 511–18.
James PA, Cader MZ, Muntoni F, Childs AM, Crow YJ, Talbot K.
Severe childhood SMA and axonal CMT due to anticodon binding
domain mutations in the GARS gene. Neurology 2006; 67: 1710–
12.
Jedrzejowska M, Jakubowska-Pietkiewicz E, Kostera-Pruszczyk A.
X-linked spinal muscular atrophy (SMAX2) caused by de novo
c.1731C4T substitution in the UBA1 gene. Neuromuscul Disord
2015; 25: 661–6.
Jedrzejowska M, Ryniewicz B, Kabzinska D, Drac H, Hausmanowa-
Petrusewicz I, Kochanski A. A patient with both Charcot-Marie-
Tooth disease (CMT 1A) and mild spinal muscular atrophy (SMA
3). Neuromuscul Disord 2008; 18: 339–41.
Jordanova A, Irobi J, Thomas FP, Van Dijck P, Meerschaert K, Dewil
M, et al. Disrupted function and axonal distribution of mutant
tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-
Tooth neuropathy. Nat Genet 2006; 38: 197–202.
Kamitani T, Kito K, Nguyen HP, Yeh ET. Characterization of
NEDD8, a developmentally down-regulated ubiquitin-like protein.
J Biol Chem 1997; 272: 28557–62.
Kapur M, Monaghan CE, Ackerman SL. Regulation of mRNA trans-
lation in neurons-A matter of life and death. Neuron 2017; 96: 616–
37.
Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch
Neurol 2011; 68: 979–84.
Kwon DY, Dimitriadi M, Terzic B, Cable C, Hart AC, Chitnis A, et al.
The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes
the degradation of survival of motor neuron protein. Mol Biol Cell
2013; 24: 1863–71.
Lao T, Chen S, Sang N. Two mutations impair the stability and func-
tion of ubiquitin-activating enzyme (E1). J Cell Physiol 2012; 227:
1561–8.
Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L,
et al. Identiﬁcation and characterization of a spinal muscular atro-
phy-determining gene. Cell 1995; 80: 155–65.
Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A,
et al. Correlation between severity and SMN protein level in spinal
muscular atrophy. Nat Genet 1997; 16: 265–9.
Ling KK, Lin MY, Zingg B, Feng Z, Ko CP. Synaptic defects in the
spinal and neuromuscular circuitry in a mouse model of spinal mus-
cular atrophy. PLoS One 2010; 5: e15457.
Liu L, Li X, Hu Z, Mao X, Zi X, Xia K, et al. IGHMBP2-related
clinical and genetic features in a cohort of Chinese Charcot-Marie-
Tooth disease type 2 patients. Neuromuscul Disord 2017a; 27: 193–
9.
Liu X, Zhao B, Sun L, Bhuripanyo K, Wang Y, Bi Y, et al. Orthogonal
ubiquitin transfer identiﬁes ubiquitination substrates under differen-
tial control by the two ubiquitin activating enzymes. Nat Commun
2017b; 8: 14286.
Marshall A, Duchen LW. Sensory system involvement in infantile
spinal muscular atrophy. J Neurol Sci 1975; 26: 349–59.
Maxwell GK, Szunyogova E, Shorrock HK, Gillingwater TH, Parson
SH. Developmental and degenerative cardiac defects in the
Taiwanese mouse model of severe spinal muscular atrophy. J Anat
2018; 232: 965–78.
Mentis GZ, Blivis D, Liu W, Drobac E, Crowder ME, Kong L, et al.
Early functional impairment of sensory-motor connectivity in a
mouse model of spinal muscular atrophy. Neuron 2011; 69: 453–
67.
Motley WW, Seburn KL, Nawaz MH, Miers KE, Cheng J, Antonellis
A, et al. Charcot-Marie-Tooth-linked mutant GARS is toxic to per-
ipheral neurons independent of wild-type GARS levels. PLoS Genet
2011; 7: e1002399.
Motley WW, Talbot K, Fischbeck KH. GARS axonopathy: not every
neuron’s cup of tRNA. Trends Neurosci 2010; 33: 59–66.
16 | BRAIN 2018: Page 16 of 17 H. K. Shorrock et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
y237/5104293 by Library - D
uncan of Jordanstone user on 24 Septem
ber 2018
Murayama S, Bouldin TW, Suzuki K. Immunocytochemical and ultra-
structural studies of Werdnig-Hoffmann disease. Acta Neuropathol
1991; 81: 408–17.
Pedurupillay CR, Amundsen SS, Baroy T, Rasmussen M, Blomhoff A,
Stadheim BF, et al. Clinical and molecular characteristics in three
families with biallelic mutations in IGHMBP2. Neuromuscul Disord
2016; 26: 570–5.
Peeters K, Palaima P, Pelayo-Negro AL, Garcia A, Gallardo E, Garcia-
Barredo R, et al. Charcot-Marie-Tooth disease type 2G redeﬁned by
a novel mutation in LRSAM1. Ann Neurol 2016; 80: 823–33.
Powis RA, Gillingwater TH. Selective loss of alpha motor neurons
with sparing of gamma motor neurons and spinal cord cholinergic
neurons in a mouse model of spinal muscular atrophy. J Anat 2016;
228: 443–51.
Powis RA, Karyka E, Boyd P, Come J, Jones RA, Zheng Y, et al.
Systemic restoration of UBA1 ameliorates disease in spinal muscular
atrophy. JCI Insight 2016; 1: e87908.
Ramser J, Ahearn ME, Lenski C, Yariz KO, Hellebrand H, von Rhein
M, et al. Rare missense and synonymous variants in UBE1 are
associated with X-linked infantile spinal muscular atrophy. Am J
Hum Genet 2008; 82: 188–93.
Reid D, Zinger Y, Raheja D. Sensory neuronopathy in spinal muscular
atrophy: a case presentation. J Clin Neuromuscul Dis 2016; 18: 44–
6.
Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L,
et al. SAHA ameliorates the SMA phenotype in two mouse models
for spinal muscular atrophy. Hum Mol Genet 2010; 19: 1492–506.
Rudnik-Schoneborn S, Goebel HH, Schlote W, Molaian S, Omran H,
Ketelsen U, et al. Classical infantile spinal muscular atrophy with
SMN deﬁciency causes sensory neuronopathy. Neurology 2003; 60:
983–7.
Savli H, Szendroi A, Romics I, Nagy B. Gene network and canonical
pathway analysis in prostate cancer: a microarray study. Exp Mol
Med 2008; 40: 176–85.
Schottmann G, Wagner C, Seifert F, Stenzel W, Schuelke M. MORC2
mutation causes severe spinal muscular atrophy-phenotype, cerebel-
lar atrophy, and diaphragmatic paralysis. Brain 2016; 139 (Pt 12):
e70.
Sevilla T, Lupo V, Martinez-Rubio D, Sancho P, Sivera R, Chumillas
MJ, et al. Mutations in the MORC2 gene cause axonal Charcot-
Marie-Tooth disease. Brain 2016; 139 (Pt 1): 62–72.
Shorrock HK, Gillingwater TH, Groen EJN. Overview of current
drugs and molecules in development for spinal muscular atrophy
therapy. Drugs 2018; 78: 293–305.
Simon CM, Dai Y, Van Alstyne M, Koutsioumpa C, Pagiazitis JG,
Chalif JI, et al. Converging mechanisms of p53 activation drive
motor neuron degeneration in spinal muscular atrophy. Cell Rep
2017; 21: 3767–80.
Sivakumar K, Kyriakides T, Puls I, Nicholson GA, Funalot B,
Antonellis A, et al. Phenotypic spectrum of disorders associated
with glycyl-tRNA synthetase mutations. Brain 2005; 128 (Pt 10):
2304–14.
Sleigh JN, Dawes JM, West SJ, Wei N, Spaulding EL, Gomez-Martin
A, et al. Trk receptor signaling and sensory neuron fate are per-
turbed in human neuropathy caused by Gars mutations. Proc Natl
Acad Sci USA 2017; 114: E3324–33.
Sleigh JN, Weir GA, Schiavo G. A simple, step-by-step dissection
protocol for the rapid isolation of mouse dorsal root ganglia.
BMC Res Notes 2016; 9: 82.
Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM,
et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal
muscular atrophy: clinical laboratory analysis of 472 400 speci-
mens. Eur J Hum Genet 2012; 20: 27–32.
Thomson AK, Somers E, Powis RA, Shorrock HK, Murphy K,
Swoboda KJ, et al. Survival of motor neurone protein is required
for normal postnatal development of the spleen. J Anat 2017; 230:
337–46.
Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S,
Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-
linked spinal muscular atrophy—a literature review. Orphanet J
Rare Dis 2017; 12: 124.
Wishart TM, Mutsaers CA, Riessland M, Reimer MM, Hunter G,
Hannam ML, et al. Dysregulation of ubiquitin homeostasis and
beta-catenin signaling promote spinal muscular atrophy. J Clin
Invest 2014; 124: 1821–34.
Wishart TM, Paterson JM, Short DM, Meredith S, Robertson KA,
Sutherland C, et al. Differential proteomics analysis of synaptic pro-
teins identiﬁes potential cellular targets and protein mediators of
synaptic neuroprotection conferred by the slow Wallerian degener-
ation (Wlds) gene. Mol Cell Proteomics 2007; 6: 1318–30.
Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB,
Steinwald P, et al. The C9orf72 repeat expansion disrupts nucleo-
cytoplasmic transport. Nature 2015; 525: 56–61.
UBA1/GARS-dependent pathology in SMA BRAIN 2018: Page 17 of 17 | 17
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
y237/5104293 by Library - D
uncan of Jordanstone user on 24 Septem
ber 2018
